Delta Capita has launched Elaris OTC, a new platform designed to automate and standardise post-trade processing for OTC derivatives. The platform enters a market that, despite its size, estimated at US$700 trillion by the Bank for International Settlements, still relies heavily on manual workflows, with around 20 percent of trades confirmed and settled manually states Delta Capita in a press release.
Elaris OTC is built on Fragmos Chain technology and enables automated matching of OTC trades and lifecycle events between counterparties. A key feature is its use of the Common Domain Model (CDM), which allows firms to translate their internal messaging formats into a common standard. This is intended to improve interoperability and reduce the operational burden that comes with custom workflows and bilateral processing.
Integration
In addition to the platform itself, Elaris OTC integrates with Delta Capita’s managed services for OTC confirmation and settlement. This setup allows firms to process trades with counterparties that may not be using the platform, offering a broader reach than technology alone typically allows. The service component is designed to provide straight-through processing across the full post-trade chain.
